ACE2 and COVID-19: If these mechanisms exist, they might be of biochemical origin (as suggested by the studies demonstrating the dysregulation of ACE2 activity following COVID-19 infection) and the eventual appearance of a humoral diabetes-specific immune response might be only a secondary effect of the viral action, although important to identify the COVID-19 patients susceptible to develop T1D.